BTIG Downgrades Bionano Genomics to Neutral
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Mark Massaro has downgraded Bionano Genomics (NASDAQ:BNGO) from a Buy to a Neutral rating.
September 10, 2024 | 11:49 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BTIG analyst Mark Massaro downgraded Bionano Genomics from Buy to Neutral, indicating a shift in sentiment and potentially affecting investor confidence.
The downgrade from Buy to Neutral by a reputable analyst like Mark Massaro at BTIG suggests a less optimistic outlook for Bionano Genomics. This could lead to a decrease in investor confidence and a potential short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100